Zinbryta is a humanized monoclonal antibody that selectively binds to the alpha chain (cluster of differentiation [CD]25) of the interleukin-2 receptor on activated T cells to prevent the immunoactivation of MS. Originally developed by PDL BioPharma, Zinbryta was licensed to Facet Biotech (which Abbott, now AbbVie, acquired in April 2010) and Biogen. Under the terms of the agreement, each party has co-promotion rights in the US and Europe while equally sharing the costs of all development activities and all operating profits, based upon the sales capabilities of each party at the time.
Zinbryta was approved for the treatment of relapsing forms of MS in the US and EU in May 2016 and July 2016, respectively. In the US, Zinbryta’s label restricts its use to the third line and later, while in July 2017, the European Medicines Agency restricted Zinbryta to patients with highly active disease that has not responded to other treatment.
LIST OF FIGURES
8 Figure 16: Gilenya sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
10 Figure 17: Lemtrada for multiple sclerosis – SWOT analysis
12 Figure 18: Datamonitor Healthcare’s drug assessment summary for Lemtrada in multiple sclerosis
LIST OF TABLES
5 Table 1: Zinbryta drug profile
6 Table 2: Zinbryta pivotal trial data in multiple sclerosis
13 Table 3: Zinbryta sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.